Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®

An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results of an open-label, post-licensure trial (EudraCT no. 2014-005078-12) to confirm the immunogenicity and safety of the Southern Hemisphere 2015...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Autores principales: Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2017
Materias:
Short Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5703369/
https://ncbi.nlm.nih.gov/pubmed/28937844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1363944
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares